Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
CAMBRIDGE, Mass., May 08, 2018 -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo”) today announced the pricing of its initial public offering of 5,312,500 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In addition, Evelo has granted the underwriters a 30-day option to purchase up to an additional 796,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. Evelo’s common stock is expected to begin trading on The Nasdaq Global Select Market on May 9, 2018 under the ticker symbol “EVLO.” All of the common stock is being offered by Evelo. The gross proceeds of the offering are expected to be $85 million, excluding any exercise of the underwriters’ option.
Morgan Stanley, Cowen and BMO Capital Markets are acting as book-running managers for the offering. JMP Securities is acting as lead manager for the offering.
A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at (631) 274-2806; or BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 10036, Attn: Equity Syndicate Department, by telephone at 800-414-3627, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Contact
Evelo Biosciences
Stefan Riley
617-704-2333
[email protected]
